N

Northern California Retina Vitreous Associates Medical Group | Mountain View, CA

Research site

(Unclaimed)

Location

2495 Hospital Drive Suite 545, Mountain View, California, United States of America

Site insights

Top conditions

Top treatments

Abicipar Pegol

AR-14034

THR-149

SF0166

Sunitinib Malate

Aflibercept

GB-102

CLS-AX

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 15 total trials

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Enrolling

Diabetic Retinopathy (DR)

Genetic: RGX-314 Dose 1

Genetic: RGX-314 Dose 2

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling

Neovascular Age-related Macular Degeneration (nAMD)

Drug: AR-14034 SR implant lower dose

Drug: AR-14034 SR implant higher dose

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (ODYSSEY)

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of supr...

Active, not recruiting

Neovascular Age-related Macular Degeneration

Drug: Aflibercept

Drug: CLS-AX